Research Article

Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants

Ahmed Bakillah,1,2 Fasika Tedla,3 Isabelle Ayoub,3 Devon John,4 Allen J. Norin,1,3 M. Mahmood Hussain,1,2 and Clinton Brown3

1Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA
2The Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY, USA
3Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA
4Department of Surgery, SUNY Downstate Medical Center, Brooklyn, NY, USA

Correspondence should be addressed to Ahmed Bakillah; abakillah@hotmail.com

Received 19 May 2015; Revised 14 October 2015; Accepted 19 October 2015

Academic Editor: Aaron L. Sverdlov

Copyright © 2015 Ahmed Bakillah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Functional abnormalities of high-density lipoprotein (HDL) could contribute to cardiovascular disease in chronic kidney disease patients. We measured a validated marker of HDL dysfunction, nitrated apolipoprotein A-I, in kidney transplant recipients to test the hypothesis that a functioning kidney transplant reduces serum nitrated apoA-I concentrations.

Methods. Concentrations of nitrated apoA-I and apoB were measured using indirect sandwich ELISA assays on sera collected from each transplant subject before transplantation and at 1, 3, and 12 months after transplantation. Patients were excluded if they have history of diabetes, treatment with lipid-lowering medications or HIV protease inhibitors, prednisone dose > 15 mg/day, nephrotic range proteinuria, serum creatinine > 1.5 mg/dL, or active inflammatory disease. Sera from 18 transplanted patients were analyzed. Four subjects were excluded due to insufficient data. Twelve and eight patients had creatinine < 1.5 mg/dL at 3 and 12 months after transplantation, respectively.

Results. Nitrated apoA-I was significantly reduced at 12 months after transplantation (p = 0.039). The decrease in apoA-I nitration was associated with significant reduction in myeloperoxidase (MPO) activity (p = 0.047). In contrast to apoA-I, nitrated apoB was not affected after kidney transplantation.

Conclusions. Patients with well-functioning grafts had significant reduction in nitrated apoA-I 12 months after kidney transplantation. Further studies are needed in a large cohort to determine if nitrated apoA-I can be used as a valuable marker for cardiovascular risk stratification in chronic kidney disease.

1. Background

Cardiovascular disease (CVD) is the leading cause of death among patients with end-stage renal disease (ESRD), accounting for approximately half of all deaths [1–4]. The major course of treatment is dialysis. Dialysis patients die at six to seven times the rate of individuals in the general population with otherwise similar risk factors. Patients with less severe stages of chronic kidney disease (CKD) also carry excess risk of cardiovascular mortality that is not explained by traditional risk factors [5, 6]. Reduction of LDL cholesterol using statins lowers risk of atherosclerotic events in nondialysis CKD patients [7, 8]. However, similar protection by statins was not observed in clinical trials involving patients on dialysis [9, 10].

It is possible that HDL’s quantity and quality may explain some of the residual risks in patients with advanced CKD. Epidemiologic studies have shown that there is a gradual increase in the risk of CVD as HDL cholesterol decreases [11, 12]. However, recent pharmacologic interventions aimed at increasing HDL abundance failed to provide clinical benefits and were associated with unexpected side effects despite promising preclinical outcomes [13, 14].

Recent studies are now focusing on assessing HDL function rather than measuring its traditional plasma concentration [15–17]. In this regard, attempts have been made to
measure nitrated apoA-I. These studies have advanced the concept that oxidative modification of HDL by MPO renders HDL dysfunctional [18–20]. Elevations in nitrated apoA-I containing HDL have been reported in atherosclerotic plaques and in plasma of CVD patients [6, 21–23].

Both qualitative and quantitative changes in HDL have been described in patients with CKD [24]. Specifically, HDL abundance is reduced and HDL acquires a proinflammatory property instead of its usual anti-inflammatory role [25, 26]. In addition, HDL from patients with CKD has reduced capacity for reverse cholesterol transport [27]. In more recent study, CKD has been shown to alter specific HDL functions linked to control of inflammation and endothelial responses [28]. Low HDL levels were associated with earlier entry in dialysis or doubling of plasma creatinine levels independently of the presence of diabetes [29]. Immunohistochemistry staining revealed higher nitrotyrosine in arteries with media calcification in CKD patients [30]. Moreover, plasma proteins of CKD patients showed a higher burden of nitration than that in healthy controls [31]. Despite these significant reports on plasma nitroproteome, the implication of nitrated lipoproteins in disease progression has not been explored in CKD patients.

Degree of nitration in apoA1-HDL has been evaluated by several methods such as mass spectrometry and Western blot analysis in different disease setting [23, 32, 33]. However, all these techniques are time-consuming and are not well adapted to high throughput screen setting. We have developed an ELISA based method to quantify serum nitrated apoA-I. We showed that CVD subjects have low total HDL but their nitrated apoA-I content is high [34]. Using the same ELISA, Vazquez et al. demonstrated a significant decrease in cholesterol efflux by ABCA1 transporters and impaired endothelial function that were associated with increased nitration of apoA-I-HDL in obese women [35]. Patients with CKD are at increased cardiovascular risk and have reduced HDL levels and altered HDL composition [36]. We have therefore investigated whether levels of circulating nitrated lipoproteins change in CKD patients treated with kidney transplantation.

2. Subjects and Methods

2.1. Patients Selection and Clinical Variable Assessment. Seventy-eight subjects were recruited from outpatient clinics of SUNY Downstate Medical Center between November 2010 and June 2013. The study was approved by the Institutional Review Board under protocol number 441318-1. Written informed consent was obtained from all study participants. All participants were adults. Kidney transplant recipients were enrolled in the study unless they met exclusion criteria. Patients with the following criteria were excluded from the study: diabetes, HIV on antiretroviral therapy, active systemic rheumatologic diseases, nephrotic syndrome, protein:creatinine ratio >1, treatment with lipid-lowering agents, body mass index (BMI) > 35, creatinine >1.5 mg/dL or estimated glomerular filtration (eGFR) <60 mL/min by Modification of Diet for Renal Disease (MDRD) equation, steroid dose >15 mg prednisone or equivalent a month or more after transplantation, and treatment with sirolimus or everolimus. All these above selection criteria would eliminate most of important confounding factors that could interfere with lipid and lipoprotein metabolism. A sample size of 12 was estimated to provide 90% power to detect difference of 448 μg/dL between pretransplant and 12-month posttransplant concentration of nitrated apoA-I at two-tailed type I error α of 0.05 using Wilcoxon signed-rank test [34, 35].

Sera were collected from each transplant subject before transplantation and at 1, 3, and 12 months after transplantation. In total, sera from eighteen transplanted patients who were eligible and presented stable kidney function were retrospectively analyzed. Four patients were excluded due to incomplete time point data. At the end, among this group, twelve and eight patients had creatinine < 1.5 mg/dL at 3 and 12 months after transplantation, respectively.

2.2. Sample Preparation and Quantification of Nitrated Lipoproteins by ELISA. Aliquots stored at −70°C were thawed and concentrations of nitrated apoA1-containing HDL were measured using a well-established sandwich ELISA method [34]. A similar sandwich ELISA has been developed to measure levels of nitrated apoB-containing LDL particles as well. The specificity of the ELISA assay was described previously [34]. The intra-assay and interassay coefficients of variation for nitrated lipoproteins and apolipoproteins measurements were less than 5% and 10%, respectively. These values are consistent with the precision of typical sandwich ELISA assays [34, 37, 38]. Briefly, diluted sera samples were incubated in 96-well plates previously coated with monoclonal anti-nitrotyrosine antibodies (EMD Millipore, Billerica, Ma, USA; clone 1A6, Cat.# 05-233), enabling the capture of total nitrated serum proteins including apoA-I and apoB. The plates were blocked in PBS buffer containing 3% bovine serum albumin (BSA) and washed with PBS-Tween (0.05%). Primary polyclonal antibodies to human apoA-I or apoB (Novus Biologicals, Littleton, CO, USA; Cat.# NB400-147 and Cat.# NB120-7616, resp.) were added to specifically bind nitrated apoA-I or nitrated apoB captured by the anti-nitrotyrosine antibodies. Standard curves were generated using increasing concentrations (1–100 ng/mL and 1–100 μg/mL) of purified human serum HDL and LDL, respectively (MyBioSource, San Diego, CA, USA; Cat.# MBS173145 and Cat.# 173147). For this purpose, monoclonal antibodies against apoA-I and apoB were immobilized in 96-well plates (4H1 and 1D1, resp., University of Ottawa Institute, Ottawa, Canada). Bound HDL (apoA-I-HDL) and LDL (apoB-LDL) were detected with alkaline phosphatase-conjugated secondary antibodies and p-Nitrophenyl phosphate (pNPP) as substrate (1 mg/mL).

Absorbance at 405 nm was measured and corrected to absorbance of control wells in which PBS-Tween was added instead of serum. Total serum apoA-I and apoB levels were determined as described previously [34, 35]. Absolute values of nitrated apolipoproteins (apoA-I and apoB) were normalized to total serum apoproteins and degree of nitration was expressed as percent.
Figure 1: Panel (a) shows changes in optical densities due to the presence of nitrated apoA-I and apoB in the serum when immobilized anti-nitrotyrosine antibodies are incubated with increasing amounts of purified HDL and LDL. The amount of nitrated apolipoproteins present in the serum as measured by ELISA using commercially available purified human HDL and LDL as standard curves. Comparison between nitrated HDL (apoA-I-HDL) and nitrated LDL (apoB-HDL) was carried out using equimolar concentrations of HDL and LDL as described in methods. Representative linear standard curves for ELISA are plotted at the top of panel (a). Values are mean of triplicates ± SD. Panel (b) shows a comparison between percent nitration of apoA-I-HDL and apoB-LDL in human serum. Sera obtained from commercially available blood donors (Bioreclamation, LLC) were used. Mean values in these sera for apoB were 149.69 ± 28.78 mg/dL (range: 114.65–204.62 mg/dL) and for apoA-I were 49.30 ± 12.96 mg/dL (range: 35.06–73.35 mg/dL). Sera were distributed in two groups (control versus CVD; N = 10/group) based on their lipids and lipoproteins levels. Concentrations of nitrated apoA-I and nitrated apoB and lipoproteins levels were measured by ELISA. Final values of nitrated apoA-I and apoB were normalized by levels of HDL and LDL, respectively. Values are mean ± SD (N = 10/group). One-way ANOVA test was performed between the two groups. Statistical significance was considered at p < 0.05.

2.3. Lipid Analyses and Enzymatic Assays. Non-HDL fraction was isolated from sera by precipitating (LDL/VLDL) with manganese chloride solution (1.06 M). After centrifugation, total cholesterol in the supernatants (HDLc) and in PBS-reconstituted precipitates (non-HDLc) was measured by colorimetric assay (Wako Diagnostics, Richmond, VA, USA; Cat.# 439-17501). Lipid peroxidation/oxidative stress were evaluated by measuring thiobarbituric acid reactive substances (TBARS) in sera. Briefly, the LDL/VLDL fraction was precipitated by 1.06 M manganese chloride and levels of TBARS were determined using OXI-TEK TBARS assay kit (ZeptoMetrix Corp., Buffalo, NY, USA; Cat.# 0801192). MPO was measured by colorimetric activity assay kit (Sigma, St. Louis, MO, USA; Cat.# MAK068).

2.4. Statistical Analysis. Only results for those with creatinine < 1.5 (those with successful transplant) are mentioned. Data for continuous variables (means ± SD) and medians (interquartile ranges) were reported. All analyses were performed using the Prism GraphPad 5.0 and Statistica 10.0 softwares. Paired values of percent nitrated apoA-I or nitrated apoB before and after transplantation were compared using nonparametric Wilcoxon signed-rank sum test. In addition, linear regression and Pearson’s correlation coefficient were used to assess associations between variables. p < 0.05 was considered statistically significant.

3. Results

3.1. Quantification of Nitrated HDL and LDL by ELISA. Figure 1(a) illustrates kinetic curve of detection of immobilized nitrotyrosine-bound lipoproteins in the wells by polyclonal antibodies against apoA-I and apoB. At equimolar concentrations, nitrated LDL binding reached saturation quicker than nitrated HDL, and the assay achieved linearity between 0 and 100 μg/mL LDL added and between 0 and 100 ng/mL HDL added (top 2 panels in Figure 1(a)). Sera from CVD patients showed a twofold increase of nitrated lipoproteins levels as compared to healthy subjects. There was approximately a sixfold increase of nitrated molecules of HDL compared to LDL (Figure 1(b)).

3.2. Clinical Characteristics of Study Cohort. Patients meeting eligibility criteria as described above were analyzed in this study. Among the 18 transplanted patients who were eligible and presented stable kidney function four patients were excluded due to incomplete data and twelve and eight patients had creatinine < 1.5 mg/dL at 3 and 12 months after transplantation, respectively. Subjects’ age in this cohort ranged from 29 to 64 years. Clinical characteristics are summarized in Table 1. At baseline, the mean HDL cholesterol and the mean non-HDL cholesterol were 52.9 ± 16.7 mg/dL (22.4–85.3) and
months after transplantation, respectively. For each subject, graft function (creatinine) study we had twelve patients and eight patients with good recipients with creatinine 3.4. Changes in Nitrated HDL and LDL in Kidney Transplant (Figures 2(c)–2(f)).

Overall, serum components such as total apoA-I and apoB did not change over time after transplantation (Figures 2(a) and 2(b)). Analysis of all fourteen patients with good graft function did not show any significant changes in nitrated lipoproteins 1 month, 3 months, and 12 months after transplantation (Figures 2(c)–2(f)).

3.3. Temporal Changes in Serum Components and Status of Nitrated Lipoproteins in the Total CKD Cohort. Overall, serum components such as total apoA-I and apoB did not change over time after transplantation (Figures 2(a) and 2(b)). Analysis of all fourteen patients with good graft function did not show any significant changes in nitrated lipoproteins 1 month, 3 months, and 12 months after transplantation (Figures 2(c)–2(f)).

3.4. Changes in Nitrated HDL and LDL in Kidney Transplant Recipients with Creatinine < 1.5 mg/dL. At the end of the study we had twelve patients and eight patients with good graft function (creatinine < 1.5 mg/dL) at 3 months and 12 months after transplantation, respectively. For each subject, we compared paired values of percent nitrated apoA-I and apoB before kidney transplantation and 3 months and 12 months after kidney transplantation. Analysis of the twelve patients that had creatinine < 1.5 mg/dL at 3 months after transplantation showed no difference in nitrated apoA-I (Figure 3(a)). At 12 months after transplantation, levels of apoA-I-HDL were slightly increased but did not reach significance (mean values were 73.4 ± 14.1 mg/dL and 76.7 ± 11.8 mg/dL at baseline and at 12 months after transplantation, resp.). This modest elevation of serum apoA-I levels was associated with significant reduction (~12%) in nitrated apoA-I (Figure 3(b)). Interestingly, six patients among eight have decreased their nitrated apoA-I by ~10%–30% 12 month after transplantation. The mean value for percent of nitrated apoA-I was significantly reduced by 18.5 ng/mg apoA-I (median value reduced by 22.5 ng/mg apoA-I; \( p = 0.039 \) 12 months after transplantation. In contrast, there were no significant changes in nitrated apoB at 3 months and 12 months after transplantation (Figures 3(c) and 3(d)). Like apoA-I, serum apoB levels tended to slightly increase but did not reach any significance (mean values were 112.46 ± 46.92 mg/dL and 141.65 ± 41.38 mg/dL at baseline and at 12 months after transplantation).

### Table 1: Clinical characteristics at baseline (before transplantation) and at 3 months and 12 months after transplantation.

| Characteristics | Baseline \((n = 14)^a\) | 3 months after transplantation \((n = 12)\) | 12 months after transplantation \((n = 8)\) |
|-----------------|------------------------|--------------------------|------------------------|
| Age at transplantation (years) | 46.6 ± 12 | 45.1 ± 11.9 | 48.3 ± 15.8 |
| Female (n) | 6 | 6 | 4 |
| BMI (kg/m²) | 25.1 ± 3.26 | 24.7 ± 3.3 | 28.9 ± 4.1* |
| Systolic BP (mmHg) | 149.5 ± 13.6 | 128.3 ± 14.7*** | 143.9 ± 18.1 |
| Diastolic BP (mmHg) | 86 ± 7.8 | 73.3 ± 11.8** | 81.5 ± 10.8 |
| Blood urea nitrogen, BUN (mg/dL) | 39.8 ± 20.8 | 22.9 ± 5.1* | 24.3 ± 8 |
| Triglycerides (mg/dL) | 121.30 [62.27–386.37] | 135.60 [73.90–246.34] | 103.40 [84.44–242.00] |
| Total cholesterol (mg/dL) | 152.4 ± 36.5 | 187.3 ± 26.4* | 198.3 ± 81.7 |
| Glyceral (mg/dL) | 28.5 ± 23.1 | 29.4 ± 11.6 | 39.1 ± 33.8 |
| Serum apoA-I (mg/dL) | 76.76 [9.68–92.61] | 71.99 [48.43–90.33] | 79.19 [45.04–89.19] |
| Serum apoB (mg/dL) | 129.13 [74.29–186.95] | 115.84 [59.21–254.67] | 158.20 [61.96–190.96] |
| Non-HDL cholesterol (LDL + VLDL, mg/dL) | 107.1 ± 22.2 | 97.6 ± 273 | 118.2 ± 18.6 |
| HDL cholesterol (mg/dL) | 52.9 ± 16.7 | 65.8 ± 30.4 | 52.6 ± 17.7 |
| TBARS (LDL + VLDL) (MDa nmol/mL) | 7.7 ± 5.7 | 7.5 ± 6.3 | 6.9 ± 3.0 |
| Myeloperoxidase (mU/mL) | 109.7 ± 27.0 | 110.4 ± 50.1 | 73.9 ± 53.0* |
| Serum creatinine (mg/dL) | 7.9 ± 2.5 | 1.2 ± 0.2*** | 1.2 ± 0.3*** |
| eGFR (mL/min) (MDRD) | 17.6 ± 14.5 | 17.4 ± 15.9 | 17.4 ± 15.9 |
| hs-CRP (mg/L) (median)b | 7.9 ± 2.5 | 1.2 ± 0.2*** | 1.2 ± 0.3*** |
| Hemoglobin (g/dL) | 11.3 ± 2 | 12.5 ± 1.4 | 13.1 ± 1.4* |
| Albumin (g/dL) | 4.1 ± 0.4 | 4.3 ± 0.2 | 4.1 ± 0.1 |

Data are presented as means ± SD or medians [interquartile ranges]. Values from baseline (before transplantation) and 3 months and 12 months (after transplantation) were compared using nonparametric test (data were significant at \( p < 0.05 \), \( p < 0.01 \), and \( p < 0.001 \)).

[a] Fourteen patients had creatinine ≤1.5 mg/dL at 3 or 12 months after transplantation; two of the 14 patients were not included at 3 months because creatinine was >1.5 mg/dL.

[b]50% of patients had values <4 (lower limit of detection for assay = 4 mg/dL).
Figure 2: Temporal changes of circulating apolipoproteins and nitrated apolipoproteins in the 14 transplant patients with good kidney function before transplantation (baseline) and 1 month, 3 months, and 12 months after transplantation. Concentrations of total serum apoA-I containing HDL and apoB containing LDL particles (a and b) and levels of nitrated apoA-I and apoB (c and d) were measured by ELISA. Percentages of nitrated apoA-I and nitrated apoB were calculated by normalizing absolute values by total amount of apoA-I and apoB, respectively (e and f). Data are represented as box-and-whisker plots. Median values from each time point are connected to generate curves.
6 Mediators of Inflammation

Figure 3: Percentage changes of nitrated lipoproteins (apoA-I-HDL and apoB-LDL) 3 months and 12 months after transplantation. Sera of twelve and eight patients with serum creatinine <1.5 mg/dL at baseline (before transplantation) and at 3 and 12 months after transplantation were analyzed by ELISA. Data represented are percent changes of nitrated apoA-I (a and b) and nitrated apoB levels (c and d) at 3 months and 12 months after transplantation, respectively. Baseline value for each patient was set at 100%. Paired values of percent nitrated apoA-I or nitrated apoB before and after transplantation were compared using nonparametric Wilcoxon signed-rank sum test. Statistical significance was considered at $p < 0.05$.

3.5. MPO Activity and Lipid Peroxidation. The decrease in apoA-I nitration 12 months after transplantation was associated with a significant reduction of MPO activity levels (Table 1; median values: 68.3 mU/mL versus 107.1 mU/mL; 32% decrease; $p = 0.047$). Lipid peroxidation as measured by TBARS assay was unchanged at 3 months and 12 months after transplantation.

3.6. Correlation between HDL and LDL Levels and Percent Nitrated apoA-I and Nitrated apoB. In our previous study, we have reported a negative relationship between degree of apoA-I-HDL and levels of circulating HDL particles in low HDL patients [34]. In this study, we sought to determine patterns of potential relationship between nitrated apolipoproteins and circulating lipoproteins in kidney transplant patients at baseline and at 3 months and 12 months after transplantation (Figure 4). There was no significant correlation between percent nitrated apoA-I and serum apoA-I levels in CKD patients before kidney transplantation (Figure 4(a)) and 3 months (Figure 4(b)) and 12 months (Figure 4(c)) after kidney transplantation. In contrast, there was a significant negative relationship between percent nitrated apoB and serum apoB levels at baseline (Figure 4(d)). This inverse correlation was maintained after 3 months (Figure 4(e)) and becomes markedly significant 12 months after kidney transplantation (Figure 4(f)). There was no significant association between nitrated apoA-I or nitrated apoB with other known inflammatory and cardiovascular markers such as hs-CRP, MPO, and Cr. (data not shown).

4. Discussion

CVD in CKD is primarily driven by oxidative stress, vascular calcification, hypertension, inflammation, and accumulation of oxidized lipoproteins as well as HDL deficiency and dysfunction [39, 40]. Recent study showed that HDL function was impaired in heart transplant recipients but it was not related to cardiac allograft vasculopathy and CRP levels [41]. To date, there is insufficient information about HDL function in kidney transplant recipients. In the present report, we demonstrate for the first time that serum nitrated apoA-I is reduced after 12 months in kidney transplant recipients with good kidney function. We examined associations of nitrated lipoproteins with serum levels of apoA-I and apoB in kidney transplant recipients. We found no significant relationship between nitrated apoA-I and levels of circulating apoA-I at baseline and at 3
months and 12 months after transplantation (Figures 4(a)–4(c)). This is not in agreement with our previous observation in CVD patients with low HDL [34]. This could be due to possible differences in lipoproteins and/or degree of nitration and patient’s population from CKD and CVD. Surprisingly, there was a significant negative correlation between percent nitrated apoB and levels of serum apoB at baseline and at 3 months and 12 months after transplantation (Figures 4(d)–4(f)). The more the serum is enriched with apoB the lesser the degree of apoB nitration is. One plausible explanation
to this unexpected observation could relate to differences in clearance of different forms of modified apoB-LDL particles. We speculate that nitrated apoB-LDL molecules would be cleared faster in the circulation than unmodified LDL resulting in lower amount of nitrated apoB. In fact, previous studies demonstrated that the accumulation of apoB-containing lipoproteins results primarily from decreased clearance rather than from increased synthesis [42]. LDL nitration has been shown to be associated with enhanced macrophages uptake when compared with oxidized LDL isolated from rheumatoid and osteoarthritis patients with CVD [43]. More studies are warranted to further elucidate the clearance of nitrated LDL particles by macrophages in CKD patients.

MPO is the main enzyme involved in chlorination and nitration of lipoproteins. Plasma MPO levels have been associated with coronary artery disease [44]. Cavusoglu et al. have shown that higher baseline MPO levels independently predict the occurrence of myocardial infarction within 2 years in patients with acute coronary syndrome [45]. High levels of nitrated HDL have been found in atherosclerotic lesions and plasma of CVD patients. In contrast, the majority of nitrated LDL mainly resides within atherosclerotic plaques [21, 46–48]. Use of drugs such as statins, beta-blockers, or ACE inhibitors has been shown to reduce MPO levels in patients with acute coronary syndrome but not in patients with stable coronary artery disease [49].

Interestingly, the decrease in apoA-I nitration 12 months after transplantation was associated with significant reduction of MPO activity (Table 1). It is not clear from our studies whether the reduced nitrated apolipoprotein A-I at 12 months is causally linked to reduced MPO activity. It is possible that reduction in serum concentration of MPO after successful kidney transplantation is due to attenuation of oxidant and inflammatory states induced by the uremia. In fact, recent study demonstrates that MPO deficiency ameliorates renal injury in the renal ablation model of CKD in mice [50]. Another study reports a negative correlation between MPO and urea and creatinine levels [51].

The evolution and severity of CKD have been shown to be associated with elevated oxidative stress [52]. Analysis of TBARS content in apoB-associated LDL/VLDL particles did not reveal any significant differences at 3 months and 12 months after transplantation compared to baseline (Table 1). This is quite different from the study by Vostalová et al. showing beneficial effect of successful kidney transplantation on the antioxidant status and lipid metabolism which resulted from both improved renal function and reduced cardiovascular complications [53]. One plausible explanation to this discrepancy could be related to differences in lipid status, patient selection, and protocol design between the two studies. In addition, the changes in lipid peroxidation products in CKD population are still debated [54–56].

In this study, a large proportion of subjects have high levels of serum apoB (>100 mg/dL; normal range ≤60 mg/dL) probably due to absence of lipid-lowering treatment in these patients and possible effect of immunosuppressive drugs. Unlike apoA-I, good kidney function did not affect degree of apoB nitration at 3 months and 12 months after transplantation (Figures 3(c) and 3(d)). These differences could be related to low levels of nitrated apoB in serum as compared to nitrated apoA-I. Alternatively, structural and molecular differences between lipoproteins may occur during progression of CKD, rendering modified LDL molecules in particular (oxidation, glycation, and carbamylation) less susceptible to nitration by MPO. Analysis of total population (all fourteen patients) with good graft function did not show any significant temporal changes in nitrated lipoproteins 1 month, 3 months, and 12 months after transplantation (Figure 2). This could be due to significant interindividual variations among patients in this small population. However, modest elevation of serum apoA-I levels was associated with significant reduction of nitrated apoA-I in kidney transplant recipients after only 12 months (Figure 3(b)). This is consistent with recent study reporting that changes of lipid profiles occur early and almost universally at 12 months after kidney transplantation [57].

One major limitation of our study is the small sample size due to strict patient’s exclusion criteria setting. Nevertheless, none of our patients had received lipid-lowering therapy that could affect outcome of the study. Another limitation is lack of suitable normal control group (donors) for this particular setting protocol. These findings need to be confirmed in a large prospective study in order to validate the usefulness of nitrated apoA-I as independent predictor marker for CVD risk in CKD patients. More focused research is warranted to elucidate whether modified HDL in advanced CKD participates in very similar cellular processes of atherosclerosis such as foam cell formation, proliferation and migration of smooth muscle cells, and, most importantly, plaque destabilization.

5. Conclusion

In summary, we have demonstrated that patients with well-functioning kidney transplants had significant reduction in nitrated apoA-I-HDL 12 months after kidney transplantation without any major changes in nitrated apoB-LDL. Given the high cardiovascular burden of kidney transplant recipients, nitrated apoA-I may serve as valuable marker for population stratification and perhaps as a possible target for novel therapeutic strategies.

Abbreviations

ABCA1: ATP-binding cassette transporter A1
ApoA-I: Apolipoprotein A-I
ApoB: Apolipoprotein B
BUN: Blood urea nitrogen
CKD: Chronic Kidney disease
Cr.: Creatinine
CRP: C-reactive protein
CVD: Cardiovascular disease
EGFR: Estimated glomerular filtration
ELISA: Enzyme linked immunosorbent assay
ESRD: End-stage renal disease
HDL: High-density lipoprotein
LDL: Low-density lipoprotein
MDA: Malondialdehyde
MDRD: Modification of diet in renal disease

Abbreviations

ABCA1: ATP-binding cassette transporter A1
ApoA-I: Apolipoprotein A-I
ApoB: Apolipoprotein B
BUN: Blood urea nitrogen
CKD: Chronic Kidney disease
Cr.: Creatinine
CRP: C-reactive protein
CVD: Cardiovascular disease
EGFR: Estimated glomerular filtration
ELISA: Enzyme linked immunosorbent assay
ESRD: End-stage renal disease
HDL: High-density lipoprotein
LDL: Low-density lipoprotein
MDA: Malondialdehyde
MDRD: Modification of diet in renal disease
MPO: Myeloperoxidase
VLDL: Very low-density lipoprotein
TBARS: Thiobarbituric acid reactive substances.

Disclaimer

All authors agree to be accountable for all aspects of this work. Each author has participated sufficiently in this work and takes public responsibility for appropriate portions of the content.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Ahmed Bakillah performed experiments and participated in the acquisition of data and interpretation of results, wrote and revised the paper, and has given approval for the final paper. Fasika Tedla was responsible for the conception and design of the study and revising the paper and has given approval for the final paper. Isabelle Ayoub was responsible for the study design and samples collection and has given approval for the final paper. Clinton Brown was responsible for the conception and design of the study and revising the paper and has given approval for the final paper. All authors read and approved the final paper.

Acknowledgments

This study was supported by the SUNY/RF Research Collaboration Fund Grant Program (Clinton Brown) and the National Institutes of Health Grant RO1HL095924 (M. Mahmood Hussain). Ahmed Bakillah was recipient of a NIH diversity supplement award (HL095924-03S1). The authors wish to thank all patients and staff at the Clinics of SUNY Downstate Medical Center.

References

[1] G. Collins and D. Altman, “Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney scores using a primary care database,” British Journal of General Practice, vol. 62, no. 597, pp. e243–e250, 2012.
[2] T. I. Steinman, “The older patient with end-stage renal disease: is chronic dialysis the best option?” Seminars in Dialysis, vol. 25, no. 6, pp. 602–605, 2012.
[3] G. Giamouzis, A. P. Kalogeropoulos, J. Butler et al., “Epidemiology and importance of renal dysfunction in heart failure patients,” Current Heart Failure Reports, vol. 10, no. 4, pp. 411–420, 2013.
[4] R. J. Macisaac, E. I. Ekinci, and G. Jerums, “Markers of and risk factors for the development and progression of diabetic kidney disease,” American Journal of Kidney Diseases, vol. 63, supplement 2, no. 2, pp. S39–S62, 2014.
[5] N. S. Anavekar and M. A. Pfeffer, “Cardiovascular risk in chronic kidney disease,” Kidney International. Supplement, vol. 92, pp. S11–S15, 2004.
[6] X.-C. Wu, B.-C. Liu, Y.-L. Wang et al., “Prevalence of chronic kidney disease in Chinese hospitalized adult patients: investigation of 13,383 cases,” Zhonghua Yi Xue Za Zhi, vol. 87, no. 38, pp. 2672–2676, 2007.
[7] C. Baigent and M. Landry, “Study of heart and renal protection (SHARP),” Kidney International. Supplement, vol. 84, pp. S207–S210, 2003.
[8] S. C. Palmer, J. C. Craig, S. D. Navaneethan, M. Tonelli, F. Pellegrini, and G. F. M. Strippoli, “Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 157, no. 4, pp. 263–275, 2012.
[9] C. Wanner and E. Ritz, “Reducing lipids for CV protection in CKD patients—current evidence,” Kidney International, vol. 74, no. III, pp. S24–S28, 2008.
[10] B. Fellström, H. Holdaas, A. G. Jardine et al., “Cardiovascular disease in patients with renal disease: the role of statins,” Current Medical Research and Opinion, vol. 25, no. 1, pp. 271–285, 2009.
[11] E. Di Angelantonio, N. Sarwar, P. Perry et al., “Major lipids, apolipoproteins, and risk of vascular disease,” The Journal of the American Medical Association, vol. 302, no. 18, pp. 1993–2000, 2009.
[12] D. J. Rader, “Molecular regulation of HDL metabolism and function: implications for novel therapies,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3090–3100, 2006.
[13] P. J. Barter and C. L. Shear, “Aggressive management of obesity in children and young adults: the known challenges and potential opportunities,” Clinical Pharmacology and Therapeutics, vol. 81, no. 5, pp. 627–630, 2007.
[14] G. G. Schwartz, “New horizons for cholesterol ester transfer protein inhibitors,” Current Atherosclerosis Reports, vol. 14, no. 1, pp. 41–48, 2012.
[15] S. C. Gordts, N. Singh, I. Muthuramu, and B. de Geest, “Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions,” Current Molecular Medicine, vol. 14, no. 4, pp. 481–503, 2014.
[16] K. A. Rye and P. J. Barter, “Cardioprotective function of HDLs,” Current Atherosclerosis Reports, vol. 15, no. 11, pp. S24–S28, 2014.
[17] R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer, “Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?” Clinical Chemistry, vol. 55, no. 8, pp. 1462–1470, 2009.
[18] B. Pan, B. Yu, H. Ren et al., “High-density lipoprotein nitration and chlorination catalyzed by myeloperoxidase impair its effect of promoting endothelial repair,” Free Radical Biology and Medicine, vol. 60, pp. 272–281, 2013.
[19] E. Ho, K. Karimi Galougahi, C.-C. Liu, R. Bhindi, and G. A. Figtree, “Biological markers of oxidative stress: applications to cardiovascular research and practice,” Redox Biology, vol. 1, no. 1, pp. 483–491, 2013.
[20] L. Zheng, B. Nukuna, M.-L. Brennan et al., “Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation
and functional impairment in subjects with cardiovascular disease," *Journal of Clinical Investigation*, vol. 114, no. 4, pp. 529–541, 2004.

[22] K. A. Hadfield, D. I. Pattison, B. E. Brown et al., "Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypocholesteric acid (HOSCn) with hypochlorous acid (HOCl)," *Biochemical Journal*, vol. 449, no. 2, pp. 531–542, 2013.

[23] Y. Huang, J. A. Didonato, B. S. Levison et al., "An abundant dysfunctional apolipoprotein AI in human atheroma," *Nature Medicine*, vol. 20, no. 2, pp. 193–203, 2014.

[24] I. H. de Boer and J. D. Brunzell, "HDL in CKD: how good is the ‘good cholesterol’?”, *Journal of the American Society of Nephrology*, vol. 25, no. 5, pp. 871–874, 2014.

[25] H. Moradi, M. V. Pahl, R. Elahimehr, and N. D. Vaziri, "Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease," *Translational Research*, vol. 153, no. 2, pp. 77–85, 2009.

[26] N. D. Vaziri, "Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease," *Journal of Renal Nutrition*, vol. 20, no. 5, supplement, pp. S35–S43, 2010.

[27] W. H. F. Sutherland, J. Corboy, R. J. Walker, M. C. Robertson, and M. J. Ball, "Cell cholesterol transport to plasma in blood from patients with renal failure or a kidney transplant," *Nephrology Dialysis Transplantation*, vol. 10, no. 3, pp. 358–365, 1995.

[28] R. Kaseda, K. Jabs, T. E. Humeley et al., "Dysfunctional high-density lipoproteins in children with chronic kidney disease," *Metabolism*, vol. 64, no. 2, pp. 263–273, 2015.

[29] A. Baragetti, G. D. Norata, C. Sarcina et al., "High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease," *Journal of Internal Medicine*, vol. 274, no. 3, pp. 252–262, 2013.

[30] G. Guligen, M. L. Werneck, L. de Noronha et al., "Increased calcification and protein nitration in arteries of chronic kidney disease patients," *Blood Purification*, vol. 32, no. 4, pp. 296–302, 2011.

[31] M. Piroddi, A. Palmese, F. Pilolli et al., "Plasma nitroproteome of kidney disease patients," *Amino Acids*, vol. 40, no. 2, pp. 653–667, 2011.

[32] S. Pennathur, C. Bergt, B. Shao et al., "Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species," *The Journal of Biological Chemistry*, vol. 279, no. 41, pp. 42977–42983, 2004.

[33] B. Shao, C. Bergt, X. Fu et al., "Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only nitration markedly impairs ABCA1-dependent cholesterol transport," *The Journal of Biological Chemistry*, vol. 280, no. 7, pp. 5993–5993, 2005.

[34] A. Bakilah, "Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects," *Clinical Chemistry and Laboratory Medicine*, vol. 47, no. 1, pp. 60–69, 2009.

[35] E. Vazquez, A. A. Sethi, L. Freeman et al., "High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women," *The American Journal of Cardiology*, vol. 109, no. 4, pp. 527–532, 2012.

[36] O. Hasselwander, J. McEneny, D. McMaster et al., "HDL composition and HDL antioxidant capacity in patients on regular haemodialysis," *Atherosclerosis*, vol. 143, no. 1, pp. 125–133, 1999.

[37] M. M. Hussain, Y. Zhao, R. K. Kancha, B. D. Blackhart, and Z. Yao, "Characterization of recombinant human ApoB-48-containing lipoproteins in rat hepatoma McA-RH7777 cells transfected with ApoB-48 cDNA: overexpression of ApoB-48 decreases synthesis of endogenous ApoB-100," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 15, no. 4, pp. 485–494, 1995.

[38] A. Bakilah, Z. Zhou, J. Luchoomun, and M. M. Hussain, "Measurement of apolipoprotein B in various cell lines: correlation between intracellular levels and rates of secretion," *Lipids*, vol. 32, no. 10, pp. 1113–1118, 1997.

[39] K. D. Navab, O. Elboudwarej, M. Gharif et al., "Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease," *Current Pharmaceutical Design*, vol. 17, no. 1, pp. 17–20, 2011.

[40] G. Khoueiry, M. Abdallah, F. Saiful et al., "High-density lipoprotein in uremic patients: metabolism, impairment, and therapy," *International Urology and Nephrology*, vol. 46, no. 1, pp. 27–39, 2014.

[41] N. Singh, F. Jacobs, D. J. Rader, J. Vanhaecke, J. Van Cleemput, and B. De Geest, "Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients," *Journal of Heart and Lung Transplantation*, vol. 33, no. 5, pp. 499–506, 2014.

[42] A. A. Kaysen, "Lipid and lipoprotein metabolism in chronic kidney disease," *Journal of Renal Nutrition*, vol. 19, no. 1, pp. 73–77, 2009.

[43] H. R. Griffiths, S. Aldred, C. Dale et al., "Homocysteine from endothelial cells promotes LDL nitration and scavenger receptor uptake," *Free Radical Biology and Medicine*, vol. 40, no. 3, pp. 488–500, 2006.

[44] R. Zhang, M.-L. Brennan, X. Fu et al., "Association between myeloperoxidase levels and risk of coronary artery disease," *Journal of the American Medical Association*, vol. 286, no. 17, pp. 2136–2142, 2001.

[45] E. Cavusoglu, C. Ruvende, C. Eng et al., "Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome," *American Journal of Cardiology*, vol. 99, no. 10, pp. 1364–1368, 2007.

[46] B. Shao, S. Pennathur, and J. W. Heinecke, "Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions," *Journal of Biological Chemistry*, vol. 287, no. 9, pp. 6375–6386, 2012.

[47] T. K. Hsiai, J. Hwang, M. L. Barr et al., "Hemodynamics influences vascular peroxynitrite formation: implication for low-density lipoprotein apo-B-100 nitration," *Free Radical Biology and Medicine*, vol. 42, no. 4, pp. 519–529, 2007.

[48] R. T. Hamilton, L. Asatryan, J. T. Nilsen et al., "LDL protein nitration: implication for LDL protein unfolding," *Archives of Biochemistry and Biophysics*, vol. 479, no. 1, pp. 1–14, 2008.

[49] G. Ndreppea, S. Braun, A. Schönig, and A. Kastrati, "Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease," *Clinical Research in Cardiology*, vol. 100, no. 4, pp. 327–333, 2011.

[50] A. Lehners, S. Lange, G. Niemann et al., "Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice," *The American Journal of Physiology—Renal Physiology*, vol. 307, no. 4, pp. F407–F417, 2014.
A. Madhusudhana Rao, U. Anand, and C. V. Anand, “Myeloperoxidase in chronic kidney disease,” *Indian Journal of Clinical Biochemistry*, vol. 26, no. 1, pp. 28–31, 2011.

C.-H. Guo and C.-L. Wang, “Plasma aluminum is a risk factor for oxidative stress and inflammation status in hemodialysis patients,” *Clinical Biochemistry*, vol. 44, no. 16, pp. 1309–1314, 2011.

J. Vostalova, A. Galandakova, A. R. Svobodova et al., “Time-course evaluation of oxidative stress-related biomarkers after renal transplantation,” *Renal Failure*, vol. 34, no. 4, pp. 413–419, 2012.

V. Costa-Hong, L. A. Bortolotto, V. Jorgetti, F. Consolim-Colombo, E. M. Krieger, and J. J. G. De Lima, “Oxidative stress and endothelial dysfunction in chronic kidney disease,” *Arquivos Brasileiros de Cardiologia*, vol. 92, no. 5, pp. 413–418, 2009.

C. Capusa, I. Stoian, E. Rus, D. Lixandru, C. Barbulescu, and G. Mircescu, “Does dialysis modality influence the oxidative stress of uremic patients?” *Kidney and Blood Pressure Research*, vol. 35, no. 4, pp. 220–225, 2012.

K. J. Moore and E. A. Fisher, “Dysfunctional hdl takes its toll in chronic kidney disease,” *Immunity*, vol. 38, no. 4, pp. 628–630, 2013.

G. A. Spinelli, C. R. Felipe, S. I. Park, E. L. Mandia-Sampaio, H. Tedesco-Silva Jr., and J. O. Medina-Pestana, “Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen,” *Transplantation Proceedings*, vol. 43, no. 10, pp. 3730–3737, 2011.